Incyte Corporation
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology. The company generates revenue through the sale of its pharmaceutical products, such as Jakafi (ruxolitinib), as well as through collaborations and royalty agreements with other pharmaceutical companies.
The ten most recent trades of Incyte Corporation in the ARKG ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
---|---|---|---|---|
Nov 06, 2024 | Sell | $1,952,629 | 13.10% | 0.16% |
Jul 12, 2024 | Sell | $1,361,381 | 10.38% | 0.10% |
Jul 10, 2024 | Sell | $3,752,116 | 23.07% | 0.30% |
Jul 09, 2024 | Sell | $3,072,898 | 16.08% | 0.25% |
Jul 08, 2024 | Sell | $1,614,460 | 7.99% | 0.13% |
Jul 05, 2024 | Sell | $518,487 | 2.53% | 0.04% |
Apr 09, 2024 | Sell | $556,743 | 2.41% | 0.04% |
Apr 08, 2024 | Sell | $794,253 | 3.34% | 0.05% |
Apr 08, 2024 | Sell | $794,253 | 3.34% | 0.05% |
Apr 08, 2024 | Sell | $794,253 | 3.34% | 0.05% |